Cover Image
市場調查報告書

稀有血液學市場 (各產品類型:血漿衍生因子,重組因子,A型血友病,B型血友病,類血友病,後天性A型血友病,各年齡) - 全球產業分析,規模,佔有率,成長,趨勢,及2017∼2022年的預測

Rare Hematology Market (Product Type - Plasma Derived Factors, Recombinant Factors, Hemophilia A, Hemophilia B, Von Wilebrand Disease, Acquired Hemophilia A, Others; Age) - Global Industry Analysis, Size, Share, Growth, Trends & Forecast 2017 - 2022

出版商 Transparency Market Research 商品編碼 587857
出版日期 內容資訊 英文 170 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
稀有血液學市場 (各產品類型:血漿衍生因子,重組因子,A型血友病,B型血友病,類血友病,後天性A型血友病,各年齡) - 全球產業分析,規模,佔有率,成長,趨勢,及2017∼2022年的預測 Rare Hematology Market (Product Type - Plasma Derived Factors, Recombinant Factors, Hemophilia A, Hemophilia B, Von Wilebrand Disease, Acquired Hemophilia A, Others; Age) - Global Industry Analysis, Size, Share, Growth, Trends & Forecast 2017 - 2022
出版日期: 2017年11月14日 內容資訊: 英文 170 Pages
簡介

全球稀有血液學市場由於血液相關疾病的罹患率上升而穩定成長。一般認為由於早期階段進行診斷流程的需求提升,對市場成長產生很大的影響。

本報告提供全球稀有血液學市場相關調查,彙整市場概要和各產品類型,各年齡,及各地區的趨勢,打入市場的主要企業的簡介等資料。

第1章 全球預測

第2章 摘要整理

第3章 市場概要

  • 簡介
  • 市場規模與預測
  • 市場趨勢
  • 供應鏈
  • 成本結構
  • 大環境分析
  • 產品生命週期
  • 主要的法律規章
  • 生技藥品認證申請產品
  • 經銷商清單
  • 主要參與企業的各地區市場地位

第4章 市場分析與預測

  • 治療類別市場規模與預測
    • 血漿衍生因子
    • 重組因子
  • 各適應症市場規模與預測
    • A型血友病
    • B型血友病
    • 類血友病
    • 後天性A型血友病
    • 其他
  • 各年齡市場規模與預測
    • 18歲以上
    • 兒童

第5章 北美

第6章 南美

第7章 歐洲

第8章 日本

第9章 APEJ

第10章 中東·非洲

第11章 競爭環境,企業簡介

  • 企業佔有率分析
  • 競爭環境
  • 企業簡介
    • Shire plc
    • Biogen Inc.
    • Novo Nordisk A/S
    • Bayer Healthcare AG
    • Pfizer Inc.
    • PRA Health Sciences
    • Celgene Corporation
    • Alexion Pharmaceuticals, Inc.
    • Amgen Inc.

第12章 調查方法

第13章 免責聲明與聯絡處資訊

目錄

Title:
Rare Hematology Market (Product Type - Plasma Derived Factors, Recombinant Factors, Hemophilia A, Hemophilia B, Von Wilebrand Disease, Acquired Hemophilia A, Others; Age -Adult and Pediatric) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2022.

Global Rare Hematology Market: Overview

The global rare hematology market is expected to witness a healthy growth attributed to growing prevalence of blood related disorders. Surge in demand to conduct the diagnosis process at the early phase is expected to impact growth of the global rare hematology market significantly. Moreover, increasing number of clinical trials to develop enhanced treatment process is further expected to encourage the progress of the global rare hematology market. With the growing demand for shorter diagnosis procedure, hematologists are increasingly focusing on enhancing their diagnosis skills.

The report offers an in-depth insight on some crucial aspects of the global rare hematology market and provides information on the growth patterns, factors fuelling the market growth, competitive landscape and important segments.

Global Rare Hematology Market: Dynamics

Growth of the global rare hematology market is mainly bound by various macro-economic and micro-economic factors. The report reveals that the global rare hematology market is mainly driven by the growing prevalence of various blood related disorders. As majority of the treatment procedures for the hematology diseases are not certified by the FDA, the hematologists are increasingly focusing on development new and safe drug products for enhanced treatment procedure. As hundreds of the clinical trials that are at the final stage are mainly stuck in the FDA pipeline for approval and evaluation, the global rare hematology market is expected to witness an inhibiting growth. Moreover, the researchers, patients, advocacy groups and caregivers are uniting to spread awareness about the blood disorders.

On the other hand, inadequate support by the disease-specific foundations for research is expected to restrain growth of the global rare hematology market. Moreover, the patients, advocacy groups, caregivers and patients are coming together in order to spread awareness. These factors are likely to contribute towards growth of the global market.

Global Rare Hematology Market: Segmentation

The global rare hematology market is mainly segmented into treatment type, age and region. On the basis of treatment type, the global market is segmented as plasma derived factors, recombinant factors, hemophilia A, hemophilia B, von wilebrand disease, acquired hemophilia A and others. Based on age, the global market is segmented as adult and pediatric. By regions, the global rare hematology market is segmented as North America, Latin America, Europe, Japan, APEJ and MEA.

Global Rare Hematology Market: Competition

Key players operating in the global market of rare hematology are Bayer Healthcare AG, Pfizer Inc., PRA Health Sciences, Alexion Pharmaceuticals, Inc., Shire plc, Pfizer Inc., Celgene Corporation, Amgen Inc., Biogen Inc., Novo Nordisk A/S, CSL Behring LLC and PRA Health Sciences.

Table of Contents

Chapter 1 Global Outlook

Chapter 2 Global Rare Hematology Disease Treatment Market-Executive Summary

Chapter 3 Global Rare Hematology Disease Treatment Market Overview

  • 3.1 Introduction
    • 3.1.1 Global Rare Hematology Disease Treatment Market Taxonomy
    • 3.1.2 Global Rare Hematology Disease Treatment Market Definition
  • 3.2 Global Rare Hematology Disease Treatment Market Size (US$ Mn) and Forecast, 2012-2022
    • 3.2.1 Global Rare Hematology Disease Treatment Market Y-o-Y Growth
  • 3.3 Global Rare Hematology Disease Treatment Market Dynamics
  • 3.4 Supply Chain
  • 3.5 Cost Structure
  • 3.6 PESTL Analysis
  • 3.7 Product Lifecycle
  • 3.8 Key Regulations
  • 3.9 Biologics License Application (BLA) Products
  • 3.10 List of Distributors
  • 3.11 Key Participants Market Presence (Intensity Map) By Region

Chapter 4 Global Rare Hematology Disease Treatment Market Analysis and Forecast 2012-2022

  • 4.1 Global Rare Hematology Disease Treatment Market Size and Forecast by Treatment Type, 2012-2022
    • 4.1.1 Plasma Derived Factors Market Size and Forecast, 2012-2022
      • 4.1.1.1 Revenue (US$ Mn) Comparison, By Region
      • 4.1.1.2 Market Share Comparison, By Region
      • 4.1.1.3 Y-o-Y growth Comparison, By Region
    • 4.1.2 Recombinant Factors Market Size and Forecast, 2012-2022
      • 4.1.2.1 Revenue (US$ Mn) Comparison, By Region
      • 4.1.2.2 Market Share Comparison, By Region
      • 4.1.2.3 Y-o-Y growth Comparison, By Region
  • 4.2 Global Rare Hematology Disease Treatment Market Size and Forecast by Indication, 2012-2022
    • 4.2.1 Hemophilia A Disease Treatment Market Size and Forecast, 2012-2022
      • 4.2.1.1 Revenue (US$ Mn) Comparison, By Region
      • 4.2.1.2 Market Share Comparison, By Region
      • 4.2.1.3 Y-o-Y growth Comparison, By Region
    • 4.2.2 Hemophilia B Disease Treatment Market Size and Forecast, 2012-2022
      • 4.2.2.1 Revenue (US$ Mn) Comparison, By Region
      • 4.2.2.2 Market Share Comparison, By Region
      • 4.2.2.3 Y-o-Y growth Comparison, By Region
    • 4.2.3 Von Wilebrand Disease Treatment Market Size and Forecast, 2012-2022
      • 4.2.3.1 Revenue (US$ Mn) Comparison, By Region
      • 4.2.3.2 Market Share Comparison, By Region
      • 4.2.3.3 Y-o-Y growth Comparison, By Region
    • 4.2.4 Acquired Hemophilia A Disease Treatment Market Size and Forecast, 2012-2022
      • 4.2.4.1 Revenue (US$ Mn) Comparison, By Region
      • 4.2.4.2 Market Share Comparison, By Region
      • 4.2.4.3 Y-o-Y growth Comparison, By Region
    • 4.2.5 Other Disease Treatment Market Size and Forecast, 2012-2022
      • 4.2.5.1 Revenue (US$ Mn) Comparison, By Region
      • 4.2.5.2 Market Share Comparison, By Region
      • 4.2.5.3 Y-o-Y growth Comparison, By Region
  • 4.3 Global Rare Hematology Disease Treatment Market Size and Forecast by Age Group, 2012-2022
    • 4.3.1 Global Rare Hematology Disease Treatment Market for Adult (18+) Market Size and Forecast, 2012-2022
      • 4.3.1.1 Revenue (US$ Mn) Comparison, By Region
      • 4.3.1.2 Market Share Comparison, By Region
      • 4.3.1.3 Y-o-Y growth Comparison, By Region
    • 4.3.2 Global Rare Hematology Disease Treatment Market for Pediatric (0-17) Market Size and Forecast, 2012-2022
      • 4.3.2.1 Revenue (US$ Mn) Comparison, By Region
      • 4.3.2.2 Market Share Comparison, By Region
      • 4.3.2.3 Y-o-Y growth Comparison, By Region

Chapter 5 North America Rare Hematology Disease Treatment Market Analysis and Forecast, By Country, 2012-2022

  • 5.1 North America Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 5.1.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 5.1.2 Revenue (US$ Mn) Comparison, By Indication
    • 5.1.3 Revenue (US$ Mn) Comparison, By Age Group
  • 5.2 US Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 5.2.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 5.2.2 Revenue (US$ Mn) Comparison, By Indication
    • 5.2.3 Revenue (US$ Mn) Comparison, By Age Group
  • 5.3 Canada Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 5.3.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 5.3.2 Revenue (US$ Mn) Comparison, By Indication
    • 5.3.3 Revenue (US$ Mn) Comparison, By Age Group

Chapter 6 Latin America Rare Hematology Disease Treatment Market Analysis and Forecast, By Country, 2012-2022

  • 6.1 Latin America Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 6.1.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 6.1.2 Revenue (US$ Mn) Comparison, By Indication
    • 6.1.3 Revenue (US$ Mn) Comparison, By Age Group
  • 6.2 Brazil Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 6.2.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 6.2.2 Revenue (US$ Mn) Comparison, By Indication
    • 6.2.3 Revenue (US$ Mn) Comparison, By Age Group
  • 6.3 Mexico Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 6.3.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 6.3.2 Revenue (US$ Mn) Comparison, By Indication
    • 6.3.3 Revenue (US$ Mn) Comparison, By Age Group
  • 6.4 Rest of Latin America Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 6.4.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 6.4.2 Revenue (US$ Mn) Comparison, By Indication
    • 6.4.3 Revenue (US$ Mn) Comparison, By Age Group

Chapter 7 Europe Rare Hematology Disease Treatment Market Analysis and Forecast, By Country, 2012-2022

  • 7.1 Europe Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 7.1.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 7.1.2 Revenue (US$ Mn) Comparison, By Indication
    • 7.1.3 Revenue (US$ Mn) Comparison, By Age Group
  • 7.2 Germany Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 7.2.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 7.2.2 Revenue (US$ Mn) Comparison, By Indication
    • 7.2.3 Revenue (US$ Mn) Comparison, By Age Group
  • 7.3 UK Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 7.3.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 7.3.2 Revenue (US$ Mn) Comparison, By Indication
    • 7.3.3 Revenue (US$ Mn) Comparison, By Age Group
  • 7.4 France Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 7.4.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 7.4.2 Revenue (US$ Mn) Comparison, By Indication
    • 7.4.3 Revenue (US$ Mn) Comparison, By Age Group
  • 7.5 Spain Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 7.5.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 7.5.2 Revenue (US$ Mn) Comparison, By Indication
    • 7.5.3 Revenue (US$ Mn) Comparison, By Age Group
  • 7.6 Italy Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 7.6.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 7.6.2 Revenue (US$ Mn) Comparison, By Indication
    • 7.6.3 Revenue (US$ Mn) Comparison, By Age Group
  • 7.7 Rest of Europe Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 7.7.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 7.7.2 Revenue (US$ Mn) Comparison, By Indication
    • 7.7.3 Revenue (US$ Mn) Comparison, By Age Group

Chapter 8 Japan Rare Hematology Disease Treatment Market Analysis and Forecast, By Country, 2012-2022

  • 8.1 Japan Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 8.1.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 8.1.2 Revenue (US$ Mn) Comparison, By Indication
    • 8.1.3 Revenue (US$ Mn) Comparison, By Age Group

Chapter 9 APEJ Rare Hematology Disease Treatment Market Analysis and Forecast, By Country, 2012-2022

  • 9.1 APEJ Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 9.1.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 9.1.2 Revenue (US$ Mn) Comparison, By Indication
    • 9.1.3 Revenue (US$ Mn) Comparison, By Age Group
  • 9.2 China Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 9.2.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 9.2.2 Revenue (US$ Mn) Comparison, By Indication
    • 9.2.3 Revenue (US$ Mn) Comparison, By Age Group
  • 9.3 India Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 9.3.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 9.3.2 Revenue (US$ Mn) Comparison, By Indication
    • 9.3.3 Revenue (US$ Mn) Comparison, By Age Group
  • 9.4 ASEAN Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 9.4.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 9.4.2 Revenue (US$ Mn) Comparison, By Indication
    • 9.4.3 Revenue (US$ Mn) Comparison, By Age Group
  • 9.5 Australia & New Zealand Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 9.5.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 9.5.2 Revenue (US$ Mn) Comparison, By Indication
    • 9.5.3 Revenue (US$ Mn) Comparison, By Age Group
  • 9.6 Rest of APEJ Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 9.6.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 9.6.2 Revenue (US$ Mn) Comparison, By Indication
    • 9.6.3 Revenue (US$ Mn) Comparison, By Age Group

Chapter 10 MEA Rare Hematology Disease Treatment Market Analysis and Forecast, By Country, 2012-2022

  • 10.1 MEA Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 10.1.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 10.1.2 Revenue (US$ Mn) Comparison, By Indication
    • 10.1.3 Revenue (US$ Mn) Comparison, By Age Group
  • 10.2 GCC Countries Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 10.2.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 10.2.2 Revenue (US$ Mn) Comparison, By Indication
    • 10.2.3 Revenue (US$ Mn) Comparison, By Age Group
  • 10.3 South Africa Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 10.3.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 10.3.2 Revenue (US$ Mn) Comparison, By Indication
    • 10.3.3 Revenue (US$ Mn) Comparison, By Age Group
  • 10.4 Rest of MEA Rare Hematology Disease Treatment Market Size and Forecast, 2012-2022
    • 10.4.1 Revenue (US$ Mn) Comparison, By Treatment Type
    • 10.4.2 Revenue (US$ Mn) Comparison, By Indication
    • 10.4.3 Revenue (US$ Mn) Comparison, By Age Group

Chapter 11 Global Rare Hematology Disease Treatment Market - Competitive Landscape and Company Profiles

  • 11.1 Global Rare Hematology Disease Treatment Market - Company Share Analysis
  • 11.2 Global Rare Hematology Disease Treatment Market - Competitive Landscape
  • 11.3 Global Rare Hematology Disease Treatment Market - Company Profiles
    • 11.3.1 Shire plc
      • 11.3.1.1 Company Overview
      • 11.3.1.2 Product Overview
      • 11.3.1.3 Key Financials
      • 11.3.1.4 Key Developments
      • 11.3.1.5 SWOT Analysis
    • 11.3.2 Biogen Inc.
      • 11.3.2.1 Company Overview
      • 11.3.2.2 Product Overview
      • 11.3.2.3 Key Financials
      • 11.3.2.4 Key Developments
      • 11.3.2.5 SWOT Analysis
    • 11.3.3 Novo Nordisk A/S
      • 11.3.3.1 Company Overview
      • 11.3.3.2 Product Overview
      • 11.3.3.3 Key Financials
      • 11.3.3.4 Key Developments
      • 11.3.3.5 SWOT Analysis
    • 11.3.4 Bayer Healthcare AG
      • 11.3.4.1 Company Overview
      • 11.3.4.2 Product Overview
    • 11.3.5 CSL Behring LLC
      • 11.3.5.1 Company Overview
      • 11.3.5.2 Product Overview
    • 11.3.6 Pfizer Inc.
      • 11.3.6.1 Company Overview
      • 11.3.6.2 Product Overview
      • 11.3.6.3 Key Financials
      • 11.3.6.4 Key Developments
      • 11.3.6.5 SWOT Analysis
    • 11.3.7 PRA Health Sciences
      • 11.3.7.1 Company Overview
      • 11.3.7.2 Product Overview
      • 11.3.7.3 Key Financials
      • 11.3.7.4 Key Developments
    • 11.3.8 Celgene Corporation
      • 11.3.8.1 Company Overview
      • 11.3.8.2 Product Overview
      • 11.3.8.3 Key Financials
      • 11.3.8.4 Key Developments
      • 11.3.8.5 SWOT Analysis
    • 11.3.9 Alexion Pharmaceuticals, Inc.
      • 11.3.9.1 Company Overview
      • 11.3.9.2 Product Overview
      • 11.3.9.3 Key Financials
      • 11.3.9.4 Key Developments
      • 11.3.9.5 SWOT Analysis
    • 11.3.10 Amgen Inc.
      • 11.3.10.1 Company Overview
      • 11.3.10.2 Product Overview
      • 11.3.10.3 Key Financials
      • 11.3.10.4 SWOT Analysis

Chapter 12 TMR Research Methodology

Chapter 13 Disclaimer and Contact information

List of Tables

  • TABLE 1: Global Rare Hematology Disease Treatment Market Value (US$ Mn), 2012-2016
  • TABLE 2: Global Rare Hematology Disease Treatment Market Value (US$ Mn), 2017-2022
  • TABLE 3: Global Rare Hematology Disease Treatment Market Value (US$ Mn) and Y-o-Y, 2015-2022
  • TABLE 4: Global Plasma Derived Factors Segment Value (US$ Mn), By Region 2012-2016
  • TABLE 5: Global Plasma Derived Factors Segment Value (US$ Mn), By Region 2017-2022
  • TABLE 6: Global Plasma Derived Factors Segment Market Share, By Region 2012-2016
  • TABLE 7: Global Plasma Derived Factors Segment Market Share, By Region 2017-2022
  • TABLE 8: Global Plasma Derived Factors Segment Y-o-Y, By Region 2015-2022
  • TABLE 9: Global Recombinant Factors Segment Value (US$ Mn), By Region 2012-2016
  • TABLE 10: Global Recombinant Factors Segment Value (US$ Mn), By Region 2017-2022
  • TABLE 11: Global Recombinant Factors Segment Market Share, By Region 2012-2016
  • TABLE 12: Global Recombinant Factors Segment Market Share, By Region 2017-2022
  • TABLE 13: Global Recombinant Factors Segment Y-o-Y, By Region 2015-2022
  • TABLE 14: Global Hemophilia A Disease Treatment Segment Value (US$ Mn), By Region 2012-2016
  • TABLE 15: Global Hemophilia A Disease Treatment Segment Value (US$ Mn), By Region 2017-2022
  • TABLE 16: Global Hemophilia A Disease Treatment Segment Market Share, By Region 2012-2016
  • TABLE 17: Global Hemophilia A Disease Treatment Segment Market Share, By Region 2017-2022
  • TABLE 18: Global Hemophilia A Disease Treatment Segment Y-o-Y, By Region 2015-2022
  • TABLE 19: Global Hemophilia B Disease Treatment Segment Value (US$ Mn), By Region 2012-2016
  • TABLE 20: Global Hemophilia B Disease Treatment Segment Value (US$ Mn), By Region 2017-2022
  • TABLE 21: Global Hemophilia B Segment Market Share, By Region 2012-2016
  • TABLE 22: Global Hemophilia B Disease Treatment Segment Market Share, By Region 2017-2022
  • TABLE 23: Global Hemophilia B Disease Treatment Segment Y-o-Y, By Region 2015-2022
  • TABLE 24: Global Von Wilebrand Disease Treatment Segment Value (US$ Mn), By Region 2012-2016
  • TABLE 25: Global Von Wilebrand Disease Treatment Segment Value (US$ Mn), By Region 2017-2022
  • TABLE 26: Global Von Wilebrand Disease Treatment Segment Market Share, By Region 2012-2016
  • TABLE 27: Global Von Wilebrand Disease Treatment Segment Market Share, By Region 2017-2022
  • TABLE 28: Global Von Wilebrand Disease Treatment Segment Y-o-Y, By Region 2015-2022
  • TABLE 29: Global Acquired Hemophilia A Disease Treatment Segment Value (US$ Mn), By Region 2012-2016
  • TABLE 30: Global Acquired Hemophilia A Disease Treatment Segment Value (US$ Mn), By Region 2017-2022
  • TABLE 31: Global Acquired Hemophilia A Disease Treatment Segment Market Share, By Region 2012-2016
  • TABLE 32: Global Acquired Hemophilia A Disease Treatment Segment Market Share, By Region 2017-2022
  • TABLE 33: Global Acquired Hemophilia A Disease Treatment Segment Y-o-Y, By Region 2015-2022
  • TABLE 34: Global Other Disease Treatment Segment Value (US$ Mn), By Region 2012-2016
  • TABLE 35: Global Other Disease Treatment Segment Value (US$ Mn), By Region 2017-2022
  • TABLE 36: Global Other Disease Treatment Segment Market Share, By Region 2012-2016
  • TABLE 37: Global Other Disease Treatment Segment Market Share, By Region 2017-2022
  • TABLE 38: Global Other Disease Treatment Segment Y-o-Y, By Region 2015-2022
  • TABLE 39: Global Rare Hematology Disease Treatment Market for Adult (18+) Segment Value (US$ Mn), By Region 2012-2016
  • TABLE 40: Global Rare Hematology Disease Treatment Market for Adult (18+) Segment Value (US$ Mn), By Region 2017-2022
  • TABLE 41: Global Rare Hematology Disease Treatment Market for Adult (18+) Segment Market Share, By Region 2012-2016
  • TABLE 42: Global Rare Hematology Disease Treatment Market for Adult (18+) Segment Market Share, By Region 2017-2022
  • TABLE 43: Global Rare Hematology Disease Treatment Market for Adult (18+) Segment Y-o-Y, By Region 2015-2022
  • TABLE 44: Global Rare Hematology Disease Treatment Market for Pediatric (0 -17) Segment Value (US$ Mn), By Region 2012-2016
  • TABLE 45: Global Rare Hematology Disease Treatment Market for Pediatric (0 -17) Segment Value (US$ Mn), By Region 2017-2022
  • TABLE 46: Global Rare Hematology Disease Treatment Market for Pediatric (0 -17) Segment Market Share, By Region 2012-2016
  • TABLE 47: Global Rare Hematology Disease Treatment Market for Pediatric (0 -17) Segment Market Share, By Region 2017-2022
  • TABLE 48: Global Rare Hematology Disease Treatment Market for Pediatric (0 -17) Segment Y-o-Y, By Region 2015-2022
  • TABLE 49: North America Current Expenditure on Health, (% of GDP), by Country, 2010 - 2016
  • TABLE 50: North America Per Capita Health Expenditure (US$ PPP), by Country, 2010-2016
  • TABLE 51: North America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010-2016
  • TABLE 52: North America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010-2016
  • TABLE 53: North America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010-2016
  • TABLE 54: North America Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 55: North America Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 56: North America Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 57: North America Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 58: North America Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 59: North America Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 60: US Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 61: US Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 62: US Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 63: US Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 64: US Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 65: US Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 66: Canada Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 67: Canada Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 68: Canada Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 69: Canada Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 70: Canada Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 71: Canada Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 72: Latin America Current Expenditure on Health, (% of GDP), by Country, 2010 - 2016
  • TABLE 73: Latin America Per Capita Health Expenditure (US$ PPP), by Country, 2010-2016
  • TABLE 74: Latin America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010-2016
  • TABLE 75: Latin America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010-2016
  • TABLE 76: Latin America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010-2016
  • TABLE 77: Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 78: Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 79: Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 80: Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 81: Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 82: Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 83: Brazil Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 84: Brazil Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 85: Brazil Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 86: Brazil Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 87: Brazil Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 88: Brazil Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 89: Mexico Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 90: Mexico Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 91: Mexico Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 92: Mexico Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 93: Mexico Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 94: Mexico Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 95: Rest of Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 96: Rest of Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 97: Rest of Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 98: Rest of Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 99: Rest of Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 100: Rest of Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 101: Europe Current Expenditure on Health, (% of GDP), by Country, 2010 - 2016
  • TABLE 102: Europe Per Capita Health Expenditure (US$ PPP), by Country, 2010-2016
  • TABLE 103: Europe Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010-2016
  • TABLE 104: Europe Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010-2016
  • TABLE 105: Europe Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010-2016
  • TABLE 106: Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 107: Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 108: Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 109: Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 110: Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 111: Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 112: Germany Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 113: Germany Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 114: Germany Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 115: Germany Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 116: Germany Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 117: Germany Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 118: UK Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 119: UK Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 120: UK Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 121: UK Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 122: UK Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 123: UK Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 124: France Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 125: France Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 126: France Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 127: France Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 128: France Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 129: France Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 130: Spain Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 131: Spain Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 132: Spain Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 133: Spain Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 134: Spain Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 135: Spain Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 136: Italy Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 137: Italy Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 138: Italy Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 139: Italy Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 140: Italy Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 141: Italy Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 142: Rest of Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 143: Rest of Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 144: Rest of Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 145: Rest of Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 146: Rest of Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 147: Rest of Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 148: Japan Current Expenditure on Health, (% of GDP), by Country, 2010 - 2016
  • TABLE 149: Japan Per Capita Health Expenditure (US$ PPP), by Country, 2010-2016
  • TABLE 150: Japan Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010-2016
  • TABLE 151: Japan Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010-2016
  • TABLE 152: Japan Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010-2016
  • TABLE 153: Japan Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 154: Japan Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 155: Japan Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 156: Japan Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 157: Japan Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 158: Japan Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 159: APEJ Current Expenditure on Health, (% of GDP), by Country, 2010 - 2016
  • TABLE 160: APEJ Per Capita Health Expenditure (US$ PPP), by Country, 2010-2016
  • TABLE 161: APEJ Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010-2016
  • TABLE 162: APEJ Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010-2016
  • TABLE 163: APEJ Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010-2016
  • TABLE 164: APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 165: APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 166: APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 167: APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 168: APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 169: APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 170: China Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 171: China Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 172: China Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 173: China Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 174: China Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 175: China Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 176: India Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 177: India Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 178: India Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 179: India Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 180: India Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 181: India Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 182: ASEAN Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 183: ASEAN Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 184: ASEAN Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 185: ASEAN Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 186: ASEAN Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 187: ASEAN Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 188: Australia & New Zealand Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 189: Australia & New Zealand Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 190: Australia & New Zealand Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 191: Australia & New Zealand Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 192: Australia & New Zealand Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 193: Australia & New Zealand Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 194: Rest of APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 195: Rest of APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 196: Rest of APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 197: Rest of APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 198: Rest of APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 199: Rest of APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 200: MEA Current Expenditure on Health, (% of GDP), by Country, 2010 - 2016
  • TABLE 201: MEA Per Capita Health Expenditure (US$ PPP), by Country, 2010-2016
  • TABLE 202: MEA Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010-2016
  • TABLE 203: MEA Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010-2016
  • TABLE 204: MEA Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010-2016
  • TABLE 205: MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 206: MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 207: MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 208: MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 209: MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 210: MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 211: GCC Countries Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 212: GCC Countries Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 213: GCC Countries Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 214: GCC Countries Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 215: GCC Countries Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 216: GCC Countries Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 217: South Africa Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 218: South Africa Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 219: South Africa Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 220: South Africa Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 221: South Africa Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 222: South Africa Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • TABLE 223: Rest of MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • TABLE 224: Rest of MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • TABLE 225: Rest of MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • TABLE 226: Rest of MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • TABLE 227: Rest of MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • TABLE 228: Rest of MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022

List of Figures

  • FIG. 1: Global Rare Hematology Disease Treatment Market Value (US$ Mn), 2012-2016
  • FIG. 2: Global Rare Hematology Disease Treatment Market Value (US$ Mn) Forecast, 2017-2022
  • FIG. 3: Global Rare Hematology Disease Treatment Market Value (US$ Mn) and Y-o-Y, 2015-2022
  • FIG. 4: Global Plasma Derived Factors Segment Market Value (US$ Mn) By Region, 2012-2016
  • FIG. 5: Global Plasma Derived Factors Segment Market Value (US$ Mn) By Region, 2017-2022
  • FIG. 6: Global Plasma Derived Factors Segment Y-o-Y Growth Rate, By Region, 2015-2022
  • FIG. 7: Global Recombinant Factors Segment Market Value (US$ Mn) By Region, 2012-2016
  • FIG. 8: Global Recombinant Factors Segment Market Value (US$ Mn) By Region, 2017-2022
  • FIG. 9: Global Recombinant Factors Segment Y-o-Y Growth Rate, By Region, 2015-2022
  • FIG. 10: Global Hemophilia A Disease Treatment Segment Market Value (US$ Mn) By Region, 2012-2016
  • FIG. 11: Global Hemophilia A Disease Treatment Segment Market Value (US$ Mn) By Region, 2017-2022
  • FIG. 12: Global Hemophilia A Disease Treatment Segment Y-o-Y Growth Rate, By Region, 2015-2022
  • FIG. 13: Global Hemophilia B Disease Treatment Segment Market Value (US$ Mn) By Region, 2012-2016
  • FIG. 14: Global Hemophilia B Disease Treatment Segment Market Value (US$ Mn) By Region, 2017-2022
  • FIG. 15: Global Hemophilia B Disease Treatment Segment Y-o-Y Growth Rate, By Region, 2015-2022
  • FIG. 16: Global Von Wilebrand Disease Treatment Segment Market Value (US$ Mn) By Region, 2012-2016
  • FIG. 17: Global Von Wilebrand Disease Treatment Segment Market Value (US$ Mn) By Region, 2017-2022
  • FIG. 18: Global Von Wilebrand Disease Treatment Segment Y-o-Y Growth Rate, By Region, 2015-2022
  • FIG. 19: Global Acquired Hemophilia A Disease Treatment Segment Market Value (US$ Mn) By Region, 2012-2016
  • FIG. 20: Global Acquired Hemophilia A Disease Treatment Segment Market Value (US$ Mn) By Region, 2017-2022
  • FIG. 21: Global Acquired Hemophilia A Disease Treatment Segment Y-o-Y Growth Rate, By Region, 2015-2022
  • FIG. 22: Global Other Disease Treatment Segment Market Value (US$ Mn) By Region, 2012-2016
  • FIG. 23: Global Other Disease Treatment Segment Market Value (US$ Mn) By Region, 2017-2022
  • FIG. 24: Global Other Disease Treatment Segment Y-o-Y Growth Rate, By Region, 2015-2022
  • FIG. 25: Global Rare Hematology Disease Treatment Market for Adult (18+) Segment Market Value (US$ Mn) By Region, 2012-2016
  • FIG. 26: Global Rare Hematology Disease Treatment Market for Adult (18+) Segment Market Value (US$ Mn) By Region, 2017-2022
  • FIG. 27: Global Rare Hematology Disease Treatment Market for Adult (18+) Segment Y-o-Y Growth Rate, By Region, 2015-2022
  • FIG. 28: Global Rare Hematology Disease Treatment Market for Pediatric (0-17) Segment Market Value (US$ Mn) By Region, 2012-2016
  • FIG. 29: Global Rare Hematology Disease Treatment Market for Pediatric (0-17) Segment Market Value (US$ Mn) By Region, 2017-2022
  • FIG. 30: Global Rare Hematology Disease Treatment Market for Pediatric (0-17) Segment Y-o-Y Growth Rate, By Region, 2015-2022
  • FIG. 31: North America Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • FIG. 32: North America Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • FIG. 33: North America Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • FIG. 34: North America Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • FIG. 35: North America Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • FIG. 36: North America Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • FIG. 37: Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • FIG. 38: Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • FIG. 39: Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • FIG. 40: Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • FIG. 41: Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • FIG. 42: Latin America Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • FIG. 43: Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • FIG. 44: Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • FIG. 45: Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • FIG. 46: Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • FIG. 47: Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • FIG. 48: Europe Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • FIG. 49: Japan Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • FIG. 50: Japan Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • FIG. 51: Japan Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • FIG. 52: Japan Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • FIG. 53: Japan Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • FIG. 54: Japan Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • FIG. 55: APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • FIG. 56: APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • FIG. 57: APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • FIG. 58: APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • FIG. 59: APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • FIG. 60: APEJ Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
  • FIG. 61: MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2012-2016
  • FIG. 62: MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Treatment Type 2017-2022
  • FIG. 63: MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2012-2016
  • FIG. 64: MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Indication 2017-2022
  • FIG. 65: MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2012-2016
  • FIG. 66: MEA Rare Hematology Disease Treatment Market Value (US$ Mn), By Age Group 2017-2022
Back to Top